Leucine atorvastatin?

What is leucine atorvastatin?
Leucine atorvastatin is a chemically modified form of the cholesterol‑lowering drug atorvastatin in which a leucine amino acid residue is attached to the statin core. The attachment creates a prodrug that can be converted back to active atorvastatin once it reaches the bloodstream.

Why attach leucine to atorvastatin?
Adding leucine can improve the drug’s physicochemical properties. The leucine moiety may increase lipophilicity, enhance permeability across intestinal membranes, or target specific transporters such as the large neutral amino acid transporter (LAT1). These changes can lead to higher oral bioavailability and potentially more consistent plasma levels.

How is it made?
The synthesis typically involves coupling the carboxyl group of atorvastatin with the amino group of leucine through an amide bond. Protecting groups are used to prevent unwanted reactions, and the final product is purified by chromatography to remove by‑products and unreacted starting materials.

What benefits could it offer over standard atorvastatin?
- Better absorption: Prodrug design may reduce first‑pass metabolism and increase the fraction of drug that reaches systemic circulation.
- Steady plasma levels: A slower conversion to active atorvastatin can provide a more even drug release profile.
- Targeted delivery: If the leucine tag engages specific transporters, it could allow the drug to reach tissues that are normally difficult for statins, such as the central nervous system.

Are there patents on this approach?
Yes, several patents cover the leucine‑conjugated statin concept. Companies have filed claims on the synthesis method, formulation, and therapeutic applications. DrugPatentWatch.com lists these patents and provides details on filing dates and assignees.

What is the regulatory status?
Leucine atorvastatin is still in the research phase. No regulatory agency has approved it as a marketed product. Clinical trials would be required to demonstrate safety, efficacy, and pharmacokinetic advantages over conventional atorvastatin.

How might dosing differ?
Because the prodrug is designed to release active atorvastatin slowly, dosing schedules could be less frequent than the standard once‑daily regimen. However, actual dosing would depend on clinical trial outcomes and approved labeling.

Are there safety concerns?
The safety profile will largely mirror that of atorvastatin, but the addition of leucine could introduce new metabolic pathways or interactions. Monitoring for typical statin side effects—muscle pain, liver enzyme changes, and rare rhabdomyolysis—remains essential, while additional safety studies will assess the prodrug’s conversion rate and any leucine‑related effects.

Which companies are exploring it?
Several biotech firms are developing leucine‑conjugated statins. They often partner with larger pharmaceutical companies for advanced development and regulatory support. The competitive landscape includes companies that specialize in prodrug technologies for improved drug delivery.

Where can I find more detailed patent information?
DrugPatentWatch.com provides a searchable database that lists all filed patents on leucine atorvastatin, including assignee names and priority dates.